At the Berkeley Structural Genomics Center (BSGC), our goal is to obtain a nearcomplete structural complement of proteins in the minimal organisms Mycoplasma genitalium and M. pneumoniae, two closely related pathogens. Current targets for structure determination have been selected in six major stages, starting with those predicted to be most tractable to high throughput study and likely to yield new structural information. We report on the process used to select these proteins, as well as our target deselection procedure. Target 
INTRODUCTION
Mycoplasma genitalium and Mycoplasma pneumoniae were the first-sequenced members of the class Mollicutes, a group of wall-less prokaryotes distinguished by their small genome sizes; the latter characteristic has earned them the name "minimal organisms." 1, 2 Minimal organisms have been the subject of numerous experimental and computational genomic studies because of the possibility of identifying the minimal complement of genes necessary for life. [3] [4] [5] Because of their tractable size, organisms with minimal genomes have also been popular for structure and function prediction. 2,6 -13 Structural genomics is an international effort to determine the three-dimensional shapes of all important biological macromolecules, with a primary focus on proteins. Most approaches involve coarse-grained sampling of protein families, aiming to provide one structure from each family, allowing folds of all family members to be recognized by homology.
14 Several strategies for selecting proteins as targets have been proposed, including selecting all proteins in single genome, [15] [16] [17] selecting proteins that will allow a maximal number of sequences to be modeled at some level of reliability 18 -21 or selecting proteins of biological interest such as those from important biochemical pathways 22 or those thought to be unique to a particular species (ORFans). 23 Details of these target selection strategies have been reviewed extensively, 14,24 -29 and implications of future selection strategies are discussed elsewhere. 30 In the United States, the National Institutes of Health are supporting structural genomics projects at 9 pilot centers through the Protein Structure Initiative (PSI). Our work is in the Berkeley Structural Genomics Center (BSGC), one of these 9 centers. The BSGC began in September 2000, and this is a report on progress to date. Our aim is to obtain a near-complete structural complement of the proteins in M. pneumoniae and M. genitalium. As M. pneumoniae proteins are largely a superset of the proteins found in M. genitalium, 31 target selection is focused on the former proteome. Because of the relatively small size of these proteomes, it was expected that determining structures for most of the experimentally tractable proteins would be possible within the 5-year pilot period. Obtaining a near-complete structural complement of a single proteome would have the potential to enable new avenues of research that depended on this completeness. This would be analogous to the research into noncoding regions of DNA that has been enabled by the availability of complete genome sequences. Targets for the BSGC have been chosen in several stages: targets seen as "low hanging fruit" were attempted first, and later stages have targeted proteins predicted to be more experimentally difficult. Targets in later rounds were also chosen using more sophisticated bioinformatic analyses, such as domain prediction, which were not in place at the beginning of the project. Finally, target selection methods were refined somewhat, in response to early experience gained at our center and others. For example, in later target selection rounds more targets related to a single Mycoplasma protein were chosen to be experimentally studied in parallel.
One important aspect of target selection that was not fully appreciated until the project was underway was the need for target deselection. In the BSGC, we are only seeking to solve structures of proteins for which the structure can not be reliably predicted via bioinformatic methods. As new structures are constantly being solved by structural biology and structural genomics groups worldwide, it is necessary to frequently reexamine our target list and remove targets for which the structures of similar or identical proteins have been solved elsewhere. We devised an automated procedure for identifying likely candidates for target deselection. These candidates are manually examined at weekly meetings to determine if they should in fact be stopped or whether the information that could be gained by finishing the structure is worth the effort. In this report, we examine the impact of target deselection and the reasons targets have been deselected.
Each round of target selection has led to successively more coverage of the M. pneumoniae proteome. In this report, we quantify the degree of coverage on two levels. First, we examine the percentage of the proteome that could accurately be modeled. This requires at least 30% sequence identity between the experimentally solved target and the Mycoplasma protein. Second, we estimate the percentage of the proteome for which the general fold can be predicted by homology with reasonable accuracy, whether or not there is sufficient confidence in the alignment accuracy to enable accurate structural modeling. The latter is described as "coarse" coverage of protein sequence space, and the former as "fine" coverage (see http:// grants2.nih.gov/grants/guide/rfa-files/RFA-GM-05-001. html). Both of these percentages are calculated on a perprotein basis, where a protein is covered if any part can be structurally predicted, and per-residue, where we consider the ability to model each amino acid.
We also examine how successful the structural biology and structural genomics communities have been in advancing structural coverage of the M. pneumoniae proteome (at both "coarse" and "fine" degrees of coverage) and what role the BSGC has played. Finally, we discuss some of the remaining obstacles to obtaining complete structural coverage. Complete data including sequences and experimental status of BSGC targets are available in the public databases TargetDB and PEPCdb.
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MATERIALS AND METHODS Target Selection
A structural genomics target is a protein whose structure is selected for experimental characterization. BSGC targets include Mycoplasma proteins as well as their homologs from other prokaryotes. In general, all rounds of target selection involved three common steps. We started each step with the set of 677 M. pneumoniae ORFs described in the original annotation of the genome. 1 (Note that additional ORFs have been identified more recently, 33 and the current set of 687 ORFs is used throughout the remainder of this report to evaluate progress toward completion of the proteome.) Each ORF was then augmented with a family of homologs from available, fully sequenced prokaryotic genomes to make a target set. First, all target sets recognizably homologous to proteins of known structure were removed from further consideration. Next, target sets of proteins that were predicted to be unsuitable for high-throughput (HT) study (e.g., those with predicted transmembrane helices) were eliminated. Finally, specific targets were chosen from among proteins in the remaining target sets. The number of targets chosen per family, or parallelism, varied amongst selection rounds, as described below. A summary of methods used in different stages of target selection are shown in Table I . A typical round of target selection is described in more detail in Figure 1 .
To date, there have been 6 rounds of target selection. The first round of targets, which were mainly chosen in the first year of BSGC operations, were selected using a variety of ad hoc methods, or because they were of interest to the BSGC experimentalists. Some aspects of this round of target selection are described elsewhere. 34 In the second round, we introduced basic standardized methods, as explained in detail below. In the third round, more sophisticated methods of detecting currently known structures were introduced, and thresholds for identifying proteins likely to be intractable for HT study (e.g., length and percentage of low complexity or coiled coil) were increased in order to go beyond "low hanging fruit." In the fourth round, the parallelism was increased as BSGC experimen-talists began deploying more HT experimental methods, and it was noted that experimental success rates varied among similar targets from different species. In the fifth round, we chose a specialized group of targets that were more challenging to clone using automated methods. These targets presented difficulties specifically related to the genetic code used by Mycoplasma, as explained in detail below, but could not be ignored because more suitable homologs could not be identified. Finally, the sixth round of targets was chosen using a domain identification procedure, with the purpose of identifying tractable domain targets within full-length proteins that were set aside by filters in earlier rounds.
Identifying known structures
At the beginning of each round of target selection, all M. pneumoniae proteins and their homologs were considered potential targets. These were then removed from consideration if they were detectably homologous to other proteins of known structure. Similarity to known structures was detected by first assembling a database of known protein structures, the "knownstr" database, which was updated prior to each target selection round. This database contained sequences of proteins released by PDB, 35 sequences of proteins deposited in the PDB and made available while the structure is still "on hold," and sequences from TargetDB, 32 for which a structure has been solved by another structural genomics center. We also included sequences of BSGC targets that have progressed to the "Traceable Map" stage, as this usually indicates the structure will soon be completed.
During each automated target selection round, sequences of all M. pneumoniae ORFs were compared to the knownstr database using several sequence comparison tools. PSI-BLAST 36 was used in rounds 2-6. PSI-BLAST position-specific scoring matrices (PSSMs) were constructed for each M. pneumoniae ORF (or predicted domain in round 6) using 10 rounds of searching our "snr" database with a matrix inclusion threshold E-value of 10 Ϫ2 (the default value of 5 ϫ 10 Ϫ3 was used in round 2). The snr database included all sequences in the swissprot, trembl, and trembl_new files (downloaded 30 July 2001  for round 2, 30 November 2001 for round 3, 21 October  2002 for rounds 4 -5, and 26 February 2004 for round 6) from Swiss-Prot, 37 which had been filtered with the SEG 38 and PFILT 39 programs using default options. The filtering was done to reduce the chance of profile corruption, 40 which can lead to inaccurate results. The PSSMs were used to search the knownstr database, and any hits with an E-value of 10 Ϫ1 or below were eliminated from consideration as targets. This significance threshold was chosen to increase the likelihood of detecting more remote homologs, even though it had some risk of false positives being removed from the target list. After the second round, the matrix inclusion threshold was increased in order to increase the possibility of identifying remote homologs, at 10 † The number of targets selected in each round is given in parentheses next to the description of the round, followed by the numbers solved and active (neither solved nor stopped) as of 13 July 2004. The "Max Targets per MP" column refers to the maximum number of protein targets selected for each M. pneumoniae protein that met the criteria for that round. In round 5, the maximum number of targets per M. pneumoniae ORF was theoretically limited to 10 as in round 4, but was actually 1 because these proteins did not have homologs in other bacteria. the risk of a higher rate of corrupted PSSMs. Because of the latter possibility, we also used BLAST 41 and Pfam 42 in target selection rounds 3-6. All M. pneumoniae ORFs with a BLAST hit against knownstr with an E-value of 10 Ϫ1 or below were eliminated from consideration as targets, in addition to those already eliminated by PSI-BLAST. In using Pfam to detect known structures, the HMMER tool (version 2.2g in rounds 3-5, 2.3.2 in round 6) 43 was used to compare the Pfam_ls library of hidden Markov models to both the knownstr database and the database of M. pneumoniae ORFs, using the family-specific "trusted cutoff" score as a cutoff for assigning significance. We eliminated from consideration all ORFs that had a significant hit to a Pfam family that had also matched at least one known structure.
Identifying targets predictably intractable for HT study
As the next step in each target selection round, we eliminated M. pneumoniae proteins and domains that were likely to be either uninteresting or predictably intractable for HT study. These included proteins with regions of amino acids predicted to be in transmembrane segments, coiled coils, regions of low complexity. We also eliminated potential targets that were long and therefore likely to be challenging; in earlier rounds (1-2) of target selection, the length cutoff was 400 amino acids, and in later rounds (3) (4) (5) (6) it was increased to 700 amino acids. Finally, we excluded proteins annotated as ribosomal components, as these were expected to be unlikely to be stable in the absence of binding partners.
The SEG program 38 (version dated 24 May 2000) was run on all sequences to identify putative low complexity regions. Default options were used. In the round 2 of target selection, any predicted low complexity region eliminated the ORF from consideration; in rounds 3-6, low complexity was allowed if the total length of low complexity regions did not exceed 20% of the total length of the protein (or domain in round 6).
The CCP program (written by J. Kuzio at NCBI, version dated 14 June 1998), using the algorithm of Lupas, 44 was used to predict coiled coil regions in all sequences. Default options were used. Thresholds for eliminating potential targets based on coiled coil predictions were the same as those used for low complexity regions (above).
Two programs were used to identify transmembrane regions. TMHMM 2.0a 45 was used, with all default options. PHDhtm 46 version 2.1 (October 1998) was also used, with the option optHtmisitMin (an option affecting the rate of false positive transmembrane predictions) set to 0.8. Any transmembrane region predicted by either program eliminated a M. pneumoniae ORF from consideration as a target in rounds 2-5. In round 6, transmembrane predictions were used in assigning domain boundaries (see below).
Identifying domains
Some Mycoplasma ORFs that were filtered out in early selection rounds were multidomain proteins that included tractable domains of unknown structure, but had been eliminated because of homology to a single domain of known structure. Therefore, in round 6, Mycoplasma TARGET SELECTION AND DESELECTION AT THE BSGC ORFs were divided into domains before entering the target selection filters. The procedure used was the same as that used to identify domains in the ASTEROIDS data set of the ASTRAL database. 47 Hidden Markov models of AS-TRAL families and superfamilies were used to predict domains in the M. pneumoniae ORFs, using the HMMER tool with a significance cutoff of 10 Ϫ4 . BLAST was also used to compare ASTRAL sequences to all M. pneumoniae ORFs, using a significance cutoff E-value of 10 Ϫ4 . Regions of Mycoplasma sequence matching one or more ASTRAL sequences or hidden Markov models were annotated as belonging to the same SCOP 48 superfamily as the hit with the most significant E-value produced by either method. Remaining unclassified regions were annotated using Pfam 10.0, using the Pfam_ls model library and the "trusted cutoff" score for each model to determine significance. Significant hits were annotated as Pfam domains. After Pfam annotation, remaining regions of at least 20 consecutive residues were annotated as potential unclassified domains. This procedure is identical to the one documented in the release notes for ASTRAL 1.65.
Putative domains identified by the ASTRAL procedure were further split into two parts at the end of each predicted transmembrane helix, as predicted by TMHMM 2.0a. 45 Finally, putative domains shorter than 50 residues were eliminated from further consideration as targets.
Identifying particular proteins as targets
In addition to the M. pneumoniae proteins themselves, homologous proteins from other prokaryotes were also chosen as targets. Each M. pneumoniae protein (or predicted domain in round 6) that passed through the above filters was used to search the NCBI database of proteins from sequenced bacterial and archaeal genomes (ftp:// ftp.ncbi.nih.gov/genomes/Bacteria), although targets were only chosen from genomes for which the BSGC had access to purified genomic DNA. A list of all genomes from which homologous targets were chosen is given in Table S1 in the supplementary information. To find these homologs, PSI-BLAST 36 was used in rounds 2-3 (version 2.2.1) and 4 -6 (version 2.2.4). PSI-BLAST PSSMs were constructed for each M. pneumoniae ORF using 10 rounds of searching the nonredundant sequence database "snr" (as described above) with default parameters; the PSSMs were then used to search the database of genomes. BLAST version 2.2.4 was also used (with default parameters) in rounds 4 -6 to search the genome database. All proteins identified by BLAST or PSI-BLAST with E-values more significant than 10 Ϫ4 , with the region of local similarity covering at least 50 residues, were considered as possible targets. In round 6, predicted domains from M. pneumoniae were used to search for possible targets. In this case, only the local region of the homologous ORF was selected as a possible target, and we also required that the region of local similarity identified by BLAST or PSI-BLAST to cover at least 80% of the length of the putative M. pneumoniae domain. This latter restriction was intended to decrease the possibility of selecting a fragment of a domain as a target.
Once potential targets were identified for each M. pneumoniae ORF or putative domain, we selected a limited number from each family as targets. The maximum number of targets chosen for each M. pneumoniae ORF was limited to 4 in earlier rounds (2-3) of target selection, but expanded to 10 in later rounds (4 -6), after better automation became available in the BSCG experimental pipeline. Those targets were chosen as follows.
Potential targets from M. pneumoniae were always selected if they passed an additional screen to ensure they could be expressed in the E. coli expression system used at the BSGC. M. pneumoniae 49 and other related mollicutes such as Ureaplasma urealyticum 50 can use UGA codons to encode the amino acid tryptophan, whereas UGA is a stop codon in E. coli. Thus, cloned M. pneumoniae proteins with this codon would express truncated proteins in E. coli. In cases where a UGA codon was within about 30 bases of either end of the gene, it could easily be mutated to a UGG codon during cloning, using mutating PCR primers. Other UGA codons, called internal UGA codons, could only be mutated in a more difficult multistep cloning procedure. In rounds 1-4, targets with a maximum of 1 internal UGA codon were allowed. In round 5, this restriction was relaxed to allow 2-4 internal UGA codons. In round 6, because we wanted to clone targets using a fully automated protocol, no internal UGA codons were allowed.
The next highest priority targets to be selected were from thermophiles and halophiles, as these were expected to be experimentally more tractable, for example, being partially purified by heating E. coli lysate. 51 These targets, if available, were chosen in order by significance of the BLAST or PSI-BLAST similarity score. If the maximum number of targets per M. pneumoniae ORF had not been reached after choosing these targets, additional targets were chosen from mesophilic organisms, including other paralogs from M. pneumoniae. These were also chosen in order by significance, with the additional restriction that the sequences had to be at least 30% identical over an aligned region of at least 50 consecutive residues. The latter restriction was intended to ensure that a reasonably accurate model could be produced for the M. pneumoniae ORF if the structure of the mesophile protein were to be solved. Current state-of-the-art comparative modeling methods are able to produce models of medium accuracy (about 90% of the main chain modeled to within 1.5 Å RMS error) when sequence identity between the model and the template is at least 30%; below this threshold, alignment errors increase rapidly and become the major source of modeling error. 52 
Target Deselection
Because the BSGC only seeks to solve structures for protein domains for which the structure cannot be reliably predicted via bioinformatic methods, we need to frequently check whether structures similar to our targets have been solved by other groups. We stop targets for which structures of similar proteins have been solved. Most deselection analysis steps are automated. However, the final decision on whether to stop any target is performed manually. This automated analysis and manual review are both performed weekly.
Automated analysis
The automated analysis begins with using BLAST and PSI-BLAST to compare our current target sequences to the knownstr database (described above), which is updated weekly. PSI-BLAST PSSMs are constructed for each target using 10 rounds of searching the "snr" nonredundant sequence database (described above) with a matrix inclusion threshold E-value of 10 Ϫ2 . These PSSMs are used to search the knownstr database, and all hits with an E-value of 10 Ϫ2 or better result in flagging the region of target sequence corresponding to the hit. BLAST hits against knownstr with E-values of 10 Ϫ2 or better also result in flagging the region of sequence corresponding to each hit. These thresholds were chosen empirically, with the goal of being sensitive enough to detect remote homology while minimizing the time spent examining false positives.
After target residues are flagged, those proteins that possess at least one region of 50 consecutive residues not flagged by hits are automatically left in the structural genomics pipeline. This is because even if some parts of a target are found to be similar to proteins of known structure, the remaining region may potentially contain a domain for which no reliable prediction of structure could be made through the bioinformatic methods used. Targets that are similar to proteins of known structure over virtually their entire length (without a stretch of 50 consecutive residues not flagged by hits) are identified for manual review to determine whether these targets should be deselected.
Manual review of target deselection candidates
Because the bioinformatic procedure above may result in false positives, targets identified by the procedure are manually examined to determine if work should be stopped. The decision about whether to stop work on a target is made by the experimentalists working on the target and reflects a cost-benefit analysis of how much work would be required to finish the structure versus the potential for new information to be gained. This decision is informed by the degree of sequence similarity with the known structure(s) and implications for accuracy of a comparative homology model and whether functionally important residues in the known structure are conserved in the target. Generally, targets that have been crystallized are not deselected when the structure of a similar protein has been solved, because after data collection, the target structure may easily be solved using molecular replacement. If a target has not been purified, it is generally stopped if the fold prediction is thought to be reliable, even if the similarity is insufficient to allow accurate modeling. Targets that have been purified but not crystallized are usually stopped only if an accurate model can be constructed, and if crystallization trials are proceeding poorly.
After a decision is made on whether to deselect or continue work on the target, the decision is recorded. If the target is continued, it is not recommended again for deselection by the automatic procedure unless a new structure is solved that is identified as similar to the target. We are identifying ways to automatically perform much of the review process, in order to more quickly process larger numbers of targets.
Quantifying Coverage of Mycoplasma Proteomes
The ultimate goal of structural genomics is to provide structural information for the complete repertoire of biological macromolecules. In this report, we measure progress toward that goal as "coverage," the fraction of sequences or residues in a set (such as a proteome) for which structural information is available or can be inferred. If a region of sequence is at least 30% identical to a protein with experimentally determined three-dimensional structure, the region is considered covered at a "fine" level. If homology is detectable, regardless of sequence identity, the region is considered covered at a "coarse" level. Details of these calculations are described below.
Per-sequence coverage of a proteome was measured as the fraction of sequences in the proteome that have at least one region covered by structural annotation. Per-residue coverage was calculated by dividing the number of residues covered by structural annotations by the total number of residues. In the latter case, all residues between the endpoints of a local alignment (e.g., from BLAST or Pfam) were treated as covered by the annotation, whether they are aligned to a residue or a gap. We also estimated the per-residue coverage of regions of the proteome predicted to be "HT-tractable and interesting" when using highthroughput experimental methods for structure determination. For this calculation, we excluded regions predicted to be transmembrane, low complexity, or coiled coil, as well as short interstitial regions (fewer than 50 residues) between predicted transmembrane regions and regions of structural annotation. The actual number of such residues in each proteome varies slightly in each calculation, as the interstitial regions change depending on which regions are annotated as matching a domain of known structure. For example, there are more regions annotated as covered at a coarse level than at a fine level, so there are additional residues in short interstitial regions in the latter calculation. However, in general, the number of predicted HTtractable and interesting residues is about 85% of the total number of residues in each proteome. Predictions of low complexity, coiled coil, or transmembrane regions were performed during target selection, as described above. We report both variants of per-residue coverage in tables.
Our analysis of coverage is based on an updated annotation of the M. pneumoniae genome, 33 which includes 687 proteins and 239,722 residues. We also measured coverage of the M. genitalium proteome, 2 which is annotated as containing 486 proteins and 175,930 residues.
As a baseline, we calculated coverage of the M. pneumoniae and M. genitalium proteomes by known structures prior to the establishment of BSGC on 1 September 2000. We then measured coverage by structures solved by the BSGC, as well as coverage that would result if structures of targets selected in each round of target selection were successfully completed. Finally, we measured coverage by all current structures (as of 13 July 2004) in order to determine the relative impact of the BSGC's efforts.
Coarse coverage was evaluated using BLAST (2.2.4), PSI-BLAST (2.2.4), and Pfam 10.0. BLAST was used with default parameters to search each M. pneumoniae ORF against the knownstr database and a database of BSGC targets. A PSI-BLAST PSSM was constructed for each M. pneumoniae and M. genitalium ORF using 10 rounds of searching the snr nonredundant sequence database (as described above, downloaded 26 February 2004) with default parameters; the PSSMs were then used to search the knownstr database and the database of BSGC targets. An E-value cutoff of 10 Ϫ4 was used as a threshold for evaluating significance for both BLAST and PSI-BLAST; for PSI-BLAST, this corresponds to about a 1% error rate in genome annotation. 53, 54 The HMMER tool (version 2.3.2) 43 was used to compare the Pfam_ls library of hidden Markov models from Pfam 10.0 to the knownstr database, the database of M. pneumoniae and M. genitalium ORFs, and the database of BSGC targets, using the familyspecific "trusted cutoff" score as a cutoff for assigning significance. Local regions of these sequences were assigned as matching each other if they both had significant matches to the same Pfam family.
Fine coverage was evaluated using the subset of coarse coverage results produced by BLAST and PSI-BLAST for which the percentage identity calculated by (PSI-) BLAST was above 30% in the region of alignment.
RESULTS
Experimentally Difficult Regions of Mycoplasma Proteomes
The focus of BSGC effort is on aspects of the M. pneumoniae proteome that are both interesting and tractable to HT methods of structure determination. This encompasses the whole proteome of 687 ORFs, excluding all regions predicted to span the membrane, coiled coil regions, short loops between domains, and low complexity regions. Of the 687 ORFs in M. pneumoniae, 149 (21.7%) have at least one predicted transmembrane helix. Thirtythree of 687 proteins (4.8%) have at least 20% of their sequence predicted as coiled coil, and 43 of 687 proteins (6.3%) have at least 20% of their sequence predicted as low complexity. A total of 201 of 687 proteins (29.3%) were considered intractable to HT study due to meeting at least one of these three criteria. A total of 14.8% of the residues in the proteome (35,419/239,722) are in regions predicted to be either low complexity, coiled coil, or transmembrane helix, and thus either uninteresting or experimentally difficult to solve using HT methods of structure determination. An additional 3,133 residues (1.3%) in the proteome are in short (Ͻ50 residue) interstitial regions between transmembrane helices and currently known structures (at the coarse level of similarity). The percentages are similar for M. genitalium. Of 486 ORFs, 111 (22.8%) have at least one predicted transmembrane helix, 19 (3.9%) have at least 20% predicted coiled coil, and 22 (4.5%) have at least 20% predicted low complexity. A total of 136 of 486 proteins (28.0%) were considered intractable to HT study due to meeting at least one of the three criteria. A total of 14.1% of M. genitalium residues (24,880/175,930) are in regions predicted to be low complexity, coiled coil, or transmembrane helix, and an additional 738 residues (0.5%) are in the short interstitial regions described above.
Coverage by BSGC Targets
Coverage of the M. pneumoniae and M. genitalium proteomes by structures released prior to the establishment of the BSGC on 1 September 2000, and by targets in each round of target selection to date, are shown in Table  II The first round of preliminary and manually selected targets produced the greatest incremental increases in coverage. However, the parallelism in this target set was low: an average of only one to two targets were selected for each Mycoplasma protein of interest.
The next three sets of automatically selected targets each provided incremental improvements in coverage, as well as a deliberate increase in the parallelism in the pipeline. In rounds 2-3, up to four targets were chosen for each M. pneumoniae protein of interest, counting targets already chosen in other rounds and to cover other M. pneumoniae proteins. This increased the average number of targets per protein to more than 3, although there were some cases where fewer than four homologs could be found that met our criteria to be targets. In cases where multiple paralogs of a gene existed within M. pneumoniae, the number of targets per Mycoplasma ORF was sometimes more than 4, as targets chosen to cover one paralog might also be similar to others. In round 4, the maximum number of targets chosen per M. pneumoniae protein was increased to 10. However, this did not increase the actual redundancy in the pipeline as much as expected, as nearly all available homologs meeting our criteria as targets had already been chosen.
In the 4th round of target selection, 65 potential targets were eliminated by the filter that prevented targets with more than 1 internal UGA codon from being chosen. However, 46 of these rejected targets were M. pneumoniae proteins with no more tractable homologs in our dataset. In round 5, the UGA codon limit was relaxed from 1 to 4 internal UGA codons permitted in order to target some of these proteins using a more complex multistep cloning approach to mutate each of the codons to UGG. Although 33 of the 46 previously rejected targets were selected in this round, the other 13 had between 5 and 21 internal UGA codons, so were judged to be too difficult for this technique to succeed in a manner suitable for structural genomics. The 33 targets chosen led to a significant increase in coverage of M. pneumoniae: 37-43 more proteins and 10 -12% more residues depending on whether coverage is measured at the coarse or fine level. This step had a smaller impact on coverage in M. genitalium (only 13 more proteins) as most targets chosen in round 5 were unique to M. pneumoniae.
In the 6th round of target selection, individual predicted domains were selected instead of full-length targets, in order to increase the number of potential tractable targets. Domain prediction resulted in greater coverage of the Mycoplasma proteomes as well as more than doubling the parallelism in the experimental pipeline. We expect some failures of these targets because of inaccurate prediction of domain boundaries: a preliminary analysis based on successive versions of SCOP showed that the domain prediction method accurately predicts 65% of the domain boundaries to within 10 residues of the manually assigned boundaries in SCOP, and 80% of the boundaries are correctly predicted within 20 residues (unpublished). In addition, some domains are unable to fold on their own, even if the boundaries are correctly identified. However, the increased parallelism in the pipeline should partially alleviate these potential problems. Preliminary experimental success rates for these targets are reported as supplementary information.
Mycoplasma residues remaining uncovered by targets
After 6 rounds of target selection, current BSGC targets cover 550 of 687 M. pneumoniae proteins (80.1%) and 78.7% (161,281/204,812) of the HT-tractable and interesting residues at the coarse level. The remaining regions not covered by BSGC targets form 230 continuous stretches of sequence at least 50 residues long. Of these, 121 contain 1 or more internal UGA codons, so were not chosen as targets during the last round of target selection. These may be selected in future rounds of target selection, as the UGA problem may be solved by using other expression systems or by cloning homologs from other bacteria. The other 109 regions contain more than 20% predicted coiled coil or low complexity regions, or at least one transmembrane helix, which would prevent them from being chosen as targets under our current criteria. Although the coiled coil or low complexity residues in each region are not considered "HT-tractable and interesting," the other residues in each region are. One of these regions is the ribosomal protein S21, which was excluded due to potential inability to fold in the absence of binding partners, but which is not part of current ribosomal structures. The remaining 109 regions may prove to be intractable to high throughput studies.
Of plasma and Ureaplasma species, and 14 (6.1%) are in ORFans. Therefore, the remaining regions do not appear to be biased toward ORFans. For most of the 121 regions currently not selected due to UGA codons, it is likely that targets may be chosen from other species when additional genomic DNA becomes available.
Current Structural Coverage, and Impact of BSGC
As shown in Table III To date (as of 13 July 2004), the BSGC has solved 69 structures of 51 different targets (some of the structures are for the same targets, under different conditions or with bound ligands). A disproportionate number of the solved structures to date have been from thermophiles (32 of 51 solved targets, or 63%, versus 284 of 945 total targets, or 30%), which were usually selected to cover M. pneumoniae proteins at a coarse rather than fine level. Therefore, BSGC structures have had more of an impact on coarse coverage of the proteome than on fine coverage. The relative impact of BSGC structures on coverage of Mycoplasma proteomes is illustrated in Figure 2 . Coarse coverage of M. pneumoniae has increased by 29 proteins (4.3% of the 687 proteins in the proteome) due to BSGC structures, while increasing by 83 proteins (12.1%) due to all non-BSGC structural genomics and structural biology efforts over the same time period. There is significant overlap between the two groups: targets similar to 18 M. pneumoniae proteins were solved by both BSGC and non-BSGC groups. In 13 of these 18 cases, the BSGC solved and released the target structure prior to the other groups. However, even under the assumption that structures similar to all 18 M. pneumoniae proteins would have been solved in the absence of the BSGC, the 11 M. pneumoniae proteins covered by targets solved only at the BSGC account for 11.7% (11 of 94 proteins) of the total increase in coarse coverage. The 24 structures solved either solely or first at the BSGC account for 25.5% (24 of 94) of the total increase in the number of proteins with coarse coverage over the lifetime of the BSGC to date. Similarly, coarse coverage of M. genitalium has increased from 262 proteins (53.9% of the 486 proteins in the proteome) to 348 proteins (71.6%). Coverage of interesting and HT-tractable residues in M. genitalium increased from 52.4% (75,936/144,943) to 72.0% (108,155/150,312). BSGC efforts account for coverage of 25 M. genitalium proteins, 16 of which were also covered by structures solved elsewhere (although 12 of the 16 were first covered by BSGC structures). The 9 proteins for which targets were solved only at the BSGC represent 10.5% (9 of 86) of the total increase in coarse coverage of M. genitalium over the lifetime of the BSGC, whereas the 21 proteins solved either solely or first at the BSGC account for 24.4% (21 of 86) of the total increase in M. genitalium proteins covered.
Although fine coverage of both Mycoplasma proteomes increased by a smaller amount due to BSGC structures, there was less overlap with structures solved by other groups. Fine coverage of M. pneumoniae has increased by 20 proteins (2.9% of the 687 proteins in the proteome) due , a cumulative total of structures solved at the BSGC and all structures solved prior to its establishment (ϩBSGC row), all structures solved outside the BSGC, including those solved prior to the establishment of the BSGC (Non-BSGC row), and by all current structures (Current). A relative timeline of these four groups, and a histogram illustrating the coarse coverage statistics, are shown in Figure 2 . The Structures column indicates the number of entries from the knownstr database (i.e., PDB chains and structural genomics targets) that contributed to coverage in each row. The latter database includes some redundant entries; e.g., a PDB entry, a PDB "on-hold" sequence, and a structural genomics target might all refer to the same protein. Residue coverage is calculated as a percentage of all residues, and as a percentage of the residues predicted to be HT-tractable and interesting (in parentheses).
to BSGC structures, while increasing by 98 proteins (13.2%) due to all other structures solved over the same time period. Only 6 proteins overlap between the two groups, and in 4 of these 6 cases, the BSGC solved the target prior to the other groups. The 14 M. pneumoniae proteins covered only by BSGC structures account for 12.5% (14 of 112) of the total increase in fine coverage of the proteome, and the 18 proteins covered solely or first by BSGC targets account for 16.1% (18 of 112) of the increase. Fine coverage of M. genitalium has increased from 137 proteins (28.2% of the 486 proteins in the proteome) to 243 proteins (50%) over the lifetime of the BSGC. Coverage of the interesting and HT-tractable residues in M. genitalium has increased from 26.6% (37,855/142,422) to 47.1% (67,9705/144,024) during the same time period. BSGC efforts account for coverage of 17 M. genitalium proteins, 7 of which were also covered by structures solved elsewhere (5 of the 7 were first covered by BSGC structures). The remaining 10 proteins represent 9% (10 of 106) of the total increase in fine coverage of M. genitalium over the lifetime of the BSGC; proteins solved solely or first by the BSGC account for 14.2% (15 of 106) of the increase.
It is interesting to contrast the increased coverage of Mycoplasma provided by BSGC structures with coverage provided by one of the most impressive structural biology achievements made at about the same time the BSGC was getting underway: high-resolution structures of the ribosome. [55] [56] [57] Some individual ribosomal proteins had been solved prior to the first of these studies, and these prior structures contributed to fine coverage of 17 M. pneumoniae proteins (2.5% of the 687 proteins in the proteome) and coarse coverage of 21 proteins (3.1% of the proteome). Ribosomal structures currently contribute to fine coverage 47 proteins in M. pneumoniae (6.8% of the 687 proteins) and coarse coverage of 57 proteins (8.3%). Currently, all annotated ribosomal proteins in M. pneumoniae except L33 type 2, L28, and S21 are covered at least coarsely. Although ribosomal structures have had a greater impact on coverage than all structures solved at the BSGC, it is unlikely that any single macromolecular complex that is studied in the future will provide such an increase.
Impact of Target Deselection
As of 1 June 2004, 324 separate target deselection recommendations had been issued by the automated system, an average of 2.4 per week since the system was deployed in October 2001. One hundred forty-six of the suggestions were overridden, and 178 were followed, resulting in stopping work on a target. Recommendations are automatically cancelled and re-issued if additional structural information becomes available prior to the recommendation being acted on, and these statistics do not include hundreds of such cases: multiple recommendations before action was taken were treated as a single recommendation. Many of the recommendations that were issued concerned the same targets: the 146 overridden suggestions were issued on a total of 54 targets, and 30 of these targets were eventually stopped after two or more deselection recommendations. Overall, recommendations were issued on 202 separate targets, of which 178 were deselected.
Most of the target deselection recommendations took place prior to the last round (round 6) of target selection on 22 March 2004, at a time when there were fewer than 400 targets being actively worked on (neither stopped nor solved). As there are currently almost 700 active targets, we expect the number of recommendations to increase accordingly. Figure 3 shows the percentage of targets that Table III . Eight structures solved prior to the formal establishment of the BSGC that were selected as BSGC targets in round 1 are included as BSGC targets rather than pre-BSCG targets, even though they were deposited into the PDB prior to 1 September 2000.
TARGET SELECTION AND DESELECTION AT THE BSGC
were deselected over time, as a fraction of the cumulative number of targets chosen. Figure 4 shows the stages at which targets were stopped: 49 of 178 (27.5%) were stopped after the target protein was purified. About half (86 of 178, or 48.3%) of the targets were stopped because we solved a "parallel" target, and about the same number (87 of 178, or 48.9%) were stopped due to another structural genomics center or structural biology laboratory solving a structure. Only five targets have been stopped solely due to experimental difficulty, although experimental difficulty is a factor taken into consideration during the manual review phase of target deselection.
Sixty-five of the 178 deselected targets (37%) were stopped based on the sequence of a homologous protein being released by the PDB, at the time of either the deposition or release of the structure. In 13 of these cases, the recommendation to stop was based on a structure that was on hold and unavailable to us, but for which the sequence was available prior to the release of the structure. In these cases, the time between release of the sequence and release of the structure by the PDB ranged from 33 to 396 days, with an average hold time of 231.9 days. In these cases, the crystallographers' decision to release their sequences at the time of deposition allowed us to stop these targets almost 8 months earlier on average than we could have if the sequences had not been made available. In the other 52 cases, the sequence was not made available until the structure was also released. In these cases, the hold times (time between deposition and release of the structure and sequence) ranged from 19 to 1515 days, with an average hold time of 151.4 days. Had the sequences of these 52 structures been made available at the time deposition to the PDB, the deselection recommendations could have been made almost 5 months earlier on average (and in the longest case, 1QGD, in which the structure was on hold for over four years, the BSGC targets would not have been selected).
To evaluate the impact of stopping work on 178 targets, we measured incremental coverage of the M. pneumoniae proteome at coarse and fine levels that would have resulted had the targets been solved, relative to the actual current coverage. At a fine level, coverage would have been increased by 19 proteins (2.7% of the 687 proteins in the proteome, or 2.5% of interesting and HT-tractable residues), and at a coarse level, coverage would have been increased by only 1 protein (0.1% of proteins, or 0.2% of the interesting and HT-tractable residues). This is not surprising, as the target deselection procedure focuses on remote homology; if finishing a target would lead to more coverage at a fine level but not at a coarse level, the target is usually stopped.
Impact on Coverage of Other Proteomes
One of the secondary goals of choosing a minimal proteome as the focus of structural genomics efforts at the BSGC was to evaluate the impact on coverage of larger proteomes. The idea is that a minimal proteome is a ubiquitous proteome, and that the complete structural complement of a minimal proteome would serve as a platform for understanding larger proteomes. 15 In an earlier Pfam-based study, 30 we showed that maximum coverage across multiple species is obtained by solving structures from large families; solving structures of proteins not classified in large Pfam-A families has little impact on coverage of other species. We used HMMER 43 to identify all Pfam-A (version 10.0) families in our solved targets, using the "trusted cutoff" for each family as a measure of determining significance. Three of our solved targets had no hits in Pfam-A, and may represent small families restricted to a few bacteria. Pfam-A families for which the BSGC solved the first structure are shown in Table IV . All but two of these 24 families are larger than the median family size (36) in Pfam 10.0.
Using methods described elsewhere, 30 we measured coverage in several other proteomes, as well as Swiss-Prot and TrEMBL. Results are shown in Table V . Most of the 24 Pfam families match at least one family in each proteome; the total number of hits ranges from 20 in the M. jannaschii proteome to 100 in A. thaliana. Overall, the 24 
Cellular Functions of Targets
One of the goals of structural genomics is to study proteins of unknown function and "hypothetical proteins," as the three-dimensional structures of these proteins often suggest biochemical or biophysical functions. 58, 59 Biochemical and cellular functions of microbial proteins are annotated in the Comprehensive Microbial Resource. 60 The annotated functions of all M. pneumoniae and M. genitalium proteins, and our targets, are shown in Table VI .
As shown in Table VI , the majority of our targets (508 of 945, or 54%) are annotated as hypothetical proteins, unclassified function, unknown function, or not annotated. Proteins in these categories also constitute the majority of M. pneumoniae proteins (363 of 687, or 53%) and a large fraction of M. genitalium proteins (195 of 486, or 40%). Proteins in this set have relatively little structural coverage: only 35% of these M. pneumoniae proteins (127 of 363) and 50% of these M. genitalium proteins (97 of 195) are covered by current structures at a coarse level. Only cellular envelope proteins (50 in M. pneumoniae and 28 in M. genitalium) have less coverage, as expected because many of these proteins contain transmembrane regions. Although TIGR role annotations were not explicitly considered when choosing targets, this analysis shows that most currently active targets correspond to roles which have the least amount of current structural coverage.
Current Active Targets
As of 13 July 2004, there are 649 current active targets (targets that have not been solved or stopped), as shown in Table I . The distribution of experimental stages of these targets is shown in Table S2 and discussed further in the supplementary material. Of these, the vast majority (459 of 649, or 71%) were selected in the most recent round, round 6, several months before. In the prior three automated sets (rounds 2-4), approximately half of the targets (115/227) are still active, the remaining targets having been solved or stopped due to homology with a solved structure. The overall fraction of targets for which the BSGC has solved a structure in these three rounds is approximately 8% (11% in round 2, 5% in round 3, and 8% in round 4, or 19/227 overall). The fraction of solved targets is slightly higher in round 2, as expected because these targets have been active for the longest time. No targets in the final two rounds (5-6) have been solved, as they have only been active for a few months. The first round has a much higher fraction of solved targets: structures for 32 of 163 targets (20%) were solved. We suspect this is due to two factors. First, these targets have been in the experimental pipeline for longer, so there has been more time to work around experimental difficulties in a "multipath" approach 61 . Second, these targets include some targets manually selected by experimentalists as interesting, and a share of the work in these cases was done by collaborators, allowing more attention to be focused on these targets. The expected rate at which full-length targets will be solved in the future therefore probably lies somewhere between the 11% observed for round 2 and the 20% observed for round 1. Because many targets in these two rounds were deselected due to a homolog being solved at the BSGC or elsewhere (83 of 163, or 51%, in round 1, and 38 of 92, or 41%, in round 2), this fraction of targets which have been solved represents a lower bound on the percentage of targets which are tractable using our current methods. We expect the fraction of solved structures for predicted domain targets to be somewhat lower than for full-length targets, both because the targets themselves are expected to be relatively more difficult experimentally (for reasons described above) and because the The second column shows the total number of targets annotated in each role, along with the number solved and the number of currently active targets remaining. The last two columns show annotations of Mycoplasma proteomes: the first number in each column is the total number of proteins in the proteome in that role, the second is the number with some structural coverage at the "coarse" level, and the third is the number of proteins with "fine" structural coverage. parallelism in round 6 is higher, so more will be deselected as a result of solving a parallel target.
DISCUSSION
We have documented the methods of target selection and deselection deployed to date at the BSGC, demonstrating an evolving strategy that started with "low-hanging fruit:" targets that are most likely to be tractable, and least similar to currently known structures. In successive rounds of target selection, both more experimentally challenging targets as well as targets more similar to known structures were selected for experimentation. We also succeeded in increasing the parallelism of targets in our pipeline, in response to reports that homologous proteins may exhibit very different degrees of tractability. In practice, this appears to have been effective: targets that were deselected because we solved a parallel target were at a variety of stages at the time one of the parallel targets was solved.
Our target deselection procedure has been very efficient in preventing the BSGC from spending effort on targets that would result in little incremental coverage of Mycoplasma proteomes. However, a drawback of the procedure is that it requires a significant amount of human effort to manually examine new recommendations every week. As we expect the required effort will scale almost linearly with the number of active targets, structural genomics centers such as the BSGC will need to further automate target deselection as the overall throughput of structural genomics increases.
The automated procedure for recommending target deselection relies on timely availability of the sequences of newly solved structures. One of the primary sources of data is the sequences of "on hold" structures from the PDB. Upon deposition of a new structure, the authors of a PDB entry may choose whether to make the sequence available immediately or hide the sequence until release of the structure. Of the 2722 structures awaiting release today (17 August 2004) , the sequence is available for only 935; for those structures held for publication (1691 structures) or release on a future date (332), sequences are available for less than half (883/2022, or 44%). More timely access to the remaining sequences, or the ability to compare structural genomics target sequences to hidden "on-hold" sequences, would enable more efficient use of resources by the BSGC and other structural genomics centers.
Our primary goal in target selection was coverage of the tractable and interesting portions of the M. pneumoniae proteome at a coarse level of similarity. If all our current targets were solved, either at the BSGC or by the structural biology community, we would be approximately 80% of the way toward achieving that goal. Of the remaining 20%, we estimate that approximately half could be targeted with HT methods, if the procedure for introducing multiple point mutations during cloning were to be fully automated. The remaining 10% of the proteome that has not been targeted to date consists of tractable and interesting regions closely linked to experimentally problematic regions such as low complexity or transmembrane regions, and therefore may prove more resistant to HT methods. It is also unlikely that all current targets in the pipeline are actually tractable to HT study, as some targets may be unstructured in the absence of a required partner or ligand.
Our focus on coarse coverage of the proteome has led to an impressive increase in coverage with a relatively modest number of solved structures. In the nearly 4 years since September 2000, over 8000 structures have been deposited to the PDB. Although the 69 structures contributed by the BSGC account for less than 1% of that total, these structures account for approximately 25% of the total incremental increase in coarse structural coverage of the M. pneumoniae and M. genitalium proteomes during that time. Structures solved by the BSGC include the only structural representatives for 10 Pfam-A families, and were the first structural representatives for 14 additional Pfam-A families. These families are nearly ubiquitous across a wide variety of eukaryotic and prokaryotic proteomes.
